Nexcelom Bioscience Revenue and Competitors
Estimated Revenue & Valuation
- Nexcelom Bioscience's estimated annual revenue is currently $19.1M per year.
- Nexcelom Bioscience received $Undisclosed in venture funding in March 2018.
- Nexcelom Bioscience's estimated revenue per employee is $155,000
- Nexcelom Bioscience has 123 Employees.
- Nexcelom Bioscience grew their employee count by 5% last year.
Nexcelom Bioscience Competitors & Alternatives
|Competitor Name||Revenue||Number of Employees||Employee Growth||Total Funding||Valuation|
What Is Nexcelom Bioscience?
Nexcelom Bioscience is a developer and marketer of image cytometry products for cell analysis in life science and biomedical research. Products range from cell viability counters (Cellometer) to high throughput microwell image cytometry workstations (Celigo), used in thousands of research laboratories in academic institutes, and pharmaceutical and biotech companies. The company contributes to the life science industry through innovation and expertise in the science of cell counting. The product family includes instruments, consumables and reagents. Nexcelom customers engage in a wide variety of research, such as cancer research, immunology, stem cell research, and neuroscience. Nexcelom offers different Cellometer models to count and analyze cell lines and primary cells, through bright field and fluorescence imaging modes. In addition, Celigo is a powerful high image quality, high throughput image cytometry system for adherent and suspension cells in microwell plates. Nexcelom Bioscience is a fast-growing company in a huge market. With its headquarters and manufacturing facilities in the Boston area, the company currently has over 80 global employees, who are fast-paced, customer-centric, helpful to colleagues and customers, and passionate about their impact in life science.keywords:Biotechnology,Healthcare,Medical Devices,Medical Diagnostics
Number of Employees
Employee Growth %
Nexcelom Bioscience News
Nexcelom Bioscience, a leading provider of cell counting and analysis products for biomedical research and the biopharma industry, announced today that it has received a strategic investment from Ampersand Capital Partners. The funding will be primarily used to support Nexcelom's worldwide growt ...
Hemoglobinopathies Market : Type, Insights Reports With Danaher, Nexcelom Bioscience, Abbott, Bio-Rad Laboratories, NIHON KOHDEN, ...
... Automatic Cell Sorter Market Industry SWOT Analysis to 2024 Top Companies: LW Scientific, Bio-Rad Laboratories, Nexcelom Bioscience, ...
Some of key competitors or manufacturers included in the study are: , LW Scientific, Bio-Rad Laboratories, Nexcelom Bioscience, Becton ...
|Company Name||Revenue||Number of Employees||Employee Growth||Total Funding|
Nexcelom Bioscience Funding
|2018-03-21||$Undisclosed||Undisclosed||Ampersand Capital Partners||Article|